US drugmaker Pfizer said on Monday that its coronavirus vaccine, jointly developed with German biotech firm BioNTech, is 90% effective at preventing COVID-19 infections in people not known to have had the virus already.
Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings.
“The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19,” Pfizer Chairman and CEO Albert Bourla said in a statement.
UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.
— Pfizer Inc. (@pfizer) November 9, 2020
If approved, the vaccine will require patients to receive two shots, with the second coming 21 days after the first. Based on supply projections, the companies said they expect to supply up to 50 million vaccine doses globally in 2020, and up to 1.3 billion doses in 2021.
Pfizer is one of several companies with a vaccine candidate in phase three trials. The phase three trials of this vaccine candidate–BNT162b2–began on July 27.
Click here for Latest News updates and viral videos on our AI-powered smart news
For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us on Instagram